Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Phase 2 Recruiting
294 enrolled
DESTINY-BTC01
Phase 3 Recruiting
620 enrolled
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Phase 1/2 Recruiting
124 enrolled
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
Phase 1 Recruiting
160 enrolled
Beacon-BTC
Phase 3 Recruiting
480 enrolled
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Phase 1/2 Recruiting
102 enrolled
panSOHO
Phase 2 Recruiting
111 enrolled
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Phase 1/2 Recruiting
342 enrolled
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Phase 2 Recruiting
60 enrolled
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Phase 1 Recruiting
100 enrolled
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Phase 2 Recruiting
151 enrolled
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Phase 3 Recruiting
286 enrolled
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Phase 1 Recruiting
280 enrolled
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Phase 2 Recruiting
454 enrolled
Study for AZD4360 in Participants With Advanced Solid Tumours
Phase 1/2 Recruiting
117 enrolled
AB02
Phase 3 Recruiting
1,100 enrolled
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
330 enrolled
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Phase 1/2 Recruiting
135 enrolled
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Recruiting
60 enrolled
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Phase 1/2 Recruiting
147 enrolled
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Phase 1 Recruiting
60 enrolled
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Phase 1 Recruiting
171 enrolled
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Phase 2 Recruiting
224 enrolled
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Phase 2 Recruiting
520 enrolled
DVDMS
Phase 2 Recruiting
30 enrolled
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
796 enrolled
MK-9999-02A
Phase 1/2 Recruiting
220 enrolled
LNCB74-01
Phase 1 Recruiting
145 enrolled
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Phase 1/2 Recruiting
27 enrolled
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Phase 1/2 Recruiting
258 enrolled
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Phase 1/2 Recruiting
540 enrolled
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Phase 1/2 Recruiting
80 enrolled
START-001
Phase 1/2 Recruiting
365 enrolled
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
115 enrolled
Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
Phase 2/3 Recruiting
180 enrolled
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
140 enrolled
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Phase 2 Recruiting
54 enrolled
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
188 enrolled
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Phase 1/2 Recruiting
240 enrolled
Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer
Phase 2 Recruiting
80 enrolled
A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers
Phase NA Recruiting
60 enrolled
AB122 Platform Study
Phase 1 Recruiting
917 enrolled
Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer
Phase 2/3 Recruiting
128 enrolled